Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03129646
Other study ID # DNDi-MILT/PM-01-VL
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 24, 2018
Est. completion date December 11, 2020

Study information

Verified date July 2020
Source Drugs for Neglected Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.


Description:

The 2 treatment regimens to be tested are: - Arm 1: Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days - Arm 2: Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days (recruitment in this arm was discontinued under protocol v4.0 dated 22 Jul 2019) The reference arm is the current standard treatment for VL: • Arm 3: Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days The target population will be VL patients from 4 to 50 years old in order to cover both paediatric and adult population. Patients will be hospitalized for 14 days of PM and MF treatment for both arm 1 and arm 2. MF treatment will start at the same time as PM treatment and for arm 2 it will continue on an out-patient basis until completion of the 28 days treatment. SSG&PM combination therapy will be administered for 17 days according to routine VL treatment guidelines and patients will remain hospitalized for the entire duration of the treatment. All patients will be asked to return to the hospital for a full assessment on day 28, and for followup visits on day 56 and at six months. To respond to the objectives, study assessments will be carried out at screening and on days 1, 3, 7, 14, 21, 28, 56 (one-month post-treatment) and 210 (six-month post-treatment). These assessments will include clinical, parasitological, haematological, biochemistry, safety, pharmacokinetic and pharmacodynamics assessments.


Recruitment information / eligibility

Status Completed
Enrollment 439
Est. completion date December 11, 2020
Est. primary completion date December 11, 2020
Accepts healthy volunteers No
Gender All
Age group 4 Years to 50 Years
Eligibility Inclusion Criteria: - Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis - Patients aged 4 to < 50 years who are able to comply with the study protocol. - Patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parents(s) or legal guardian for patients under 18 years of age. In the case of minors, assent from the children also needs to be obtained as per each country regulatory requirements Exclusion Criteria: - Patients who are relapse cases - Patients with Para-Kala azar dermal leishmaniasis grade 3 - Patients who have received any anti-leishmanial drugs in the last 6 months - Patients with severe malnutrition (for children aged <5 years: weight-for-height WHO reference curves by sex, z score <-3; for children patients 5-18 years: BMI-for-age WHO reference curves by sex, z score < -3; for adults >18 years: BMI < 16)* - Patients with positive HIV diagnosis - Patients with previous history of hypersensitivity reaction or known drug class allergy to any of the study treatments - Patients with previous history of cardiac arrhythmia or with a clinically significant abnormal ECG - Patients suffering from a concomitant severe infection such as TB, schistosomiasis or any other serious underlying disease (e.g. cardiac, renal, hepatic) or chronic condition which would preclude evaluation of the patient's response to study medication - Pregnant or lactating women - Female patients of child bearing age who do not accept to have a pregnancy test done at screening and/or who do not agree to use contraception from treatment period until 5 months after the end of treatment (see section 15.2) - Patients with haemoglobin < 5g/dl - Patients with signs of severe VL according to Investigator's judgement, requiring an indication for AmBisome therapy based on the clinical manifestations (such as jaundice, bleeding, edema) and clinically significant abnormalities in the following laboratory parameters: haemoglobin, WBC, platelets, liver enzymes (ALT and AST), total bilirubin and creatinine - Patients with pre-existing hearing loss based on audiometry at baseline - Patients who cannot comply with the planned scheduled visits and procedures of the study protocol - Note: for Ethiopia only: Patients with severe malnutrition (for patients 4-18 years: MUAC cut-off based on MUAC-for-height reference table; for patients > 18 years: MUAC < 170 mm)

Study Design


Intervention

Drug:
Miltefosine
Miltefosine 10mg and 50mg capsules
Paromomycin
Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
Sodium stibogluconate
Sodium stibogluconate 33% 30 ml inj.

Locations

Country Name City State
Ethiopia Abdurafi MSF Health Center Abderafi Amhara
Ethiopia University Hospital of Gondar Gondar
Kenya Kacheliba Hospital Kapenguria West Pokot
Sudan El Hassan Centre for Tropical Medicine Doka Gedaref
Sudan Tabarak Allah MSF Hospital Gadarif Gedaref
Sudan Um El Kher Hospital Gedaref
Uganda Amudat Hospital Amudat Karamoja

Sponsors (6)

Lead Sponsor Collaborator
Drugs for Neglected Diseases Kenya Medical Research Institute, Makerere University, The Institute of Endemic Diseases (IEND), University of Khartoum, The Netherlands Cancer Institute, University of Gondar

Countries where clinical trial is conducted

Ethiopia,  Kenya,  Sudan,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Definitive Cure Cure at 6 months follow up defined as absence of clinical signs and symptoms of VL at D210 and no requirement for rescue treatment during the trial (e.g. no relapse or initial treatment failure). 6 months follow-up (Day 210)
Secondary Incidence of Treatment-Emergent Adverse Events Frequency of SAEs and AEs requiring treatment discontinuation
Frequency and severity of adverse events from the start of treatment through the last visit, at day 210.
From Screening to day 210
Secondary Initial cure at day 28 Initial cure: cure at the end of treatment (Day 28), defined as recovery of clinical signs and symptoms; absence of parasites (microscopy) and no rescue treatment administered up to and including Day 28.
Probable cure: absence of clinical signs and symptoms of VL at D56 and no prior requirement for rescue medication.
Initial cure: day 28; Probable cure: day 56
Secondary Pharmacokinetics of paromomycin and miltefosine Total and partial blood plasma exposure to paromomycin and miltefosine defined as the area under the concentration-time curve During treatment, at 1 month (day 56) and 6 months (day 210) follow-up
Secondary Pharmacodynamics Blood parasite clearance over time (qualitative and quantitative), as measured by qPCR from blood samples From baseline until day 210, and at any suspicion of relapse during the trial.
Secondary Compliance to miltefosine treatment in an outpatient setting Compliance to MF treatment in an outpatient setting will be assessed through patients' hospital records history, drug accountability and PK measurements. Day 15 to day 28 miltefosine treatment
See also
  Status Clinical Trial Phase
Terminated NCT02839603 - Asymptomatic Leishmania Infection in HIV Patients
Completed NCT00370825 - Combination Chemotherapy for the Treatment of Indian Kala-Azar Phase 2
Recruiting NCT05426577 - Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Completed NCT01069198 - A Community Trial for Visceral Leishmaniasis (VL) N/A
Completed NCT00371995 - Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Phase 2
Completed NCT00604955 - Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Phase 4
Completed NCT01032187 - Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Phase 4
Completed NCT00342823 - Immunogenetics of Visceral Leishmaniasis N/A
Completed NCT04003532 - LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Terminated NCT01980199 - Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Phase 2
Completed NCT00255567 - Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Phase 3
Not yet recruiting NCT06118749 - Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
Recruiting NCT04342715 - A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Completed NCT02431143 - Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Phase 2
Completed NCT01122771 - Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Phase 3
Completed NCT03636659 - Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Phase 1
Not yet recruiting NCT01566552 - Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Phase 4
Completed NCT00696969 - Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Phase 3
Completed NCT00318721 - Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar N/A
Completed NCT00216346 - Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Phase 3